Nov 1, 2026 —
The European Society of Gene and Cell Therapy held its 33rd annual congress in Hamburg, and the meeting, together with the FDA’s new draft guidance on individualized therapies, helped send gene-editing stocks up sharply on the week.
Among the highlights, base-editing and prime-editing pioneer David Liu pointed to growing progress toward disease-agnostic gene editing: approaches designed to be retargeted quickly across many different mutations rather than built one disease at a time.
The mood reflected a field regaining momentum after a difficult stretch, with editing platforms and delivery advances front and center.
